Humacyte, Inc. Share Price & Technical Analysis
HUMA · $1.09 (+3.81%)
Healthcare / Biotechnology
$1.09
+3.81%
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
25% return in May, 58% avg return in past 3 year May month.
23% return in 2026, 33% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 10% | -45% | 33% | 25% | – | – | – | – | – | – | – | 23% |
| 25 | -8% | -23% | -50% | -12% | 80% | -22% | 14% | -32% | 13% | 0% | -18% | -23% | -80% |
| 24 | 14% | 26% | 3% | 26% | 88% | -36% | 76% | -36% | -10% | -6% | -12% | 11% | 144% |
| 23 | 18% | 15% | 3% | 3% | 6% | -17% | 14% | 19% | -26% | -30% | 23% | 8% | 36% |
| 22 | -25% | 9% | 16% | -1% | -24% | -42% | 6% | 6% | -11% | 3% | -11% | -32% | -106% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Strong
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$207.70M
P/E ratio
—
52W high
$2.93
52W low
$0.55
Volume
26,48,818
Beta
2.31
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Humacyte, Inc. share price today?
- Humacyte, Inc. (HUMA) last traded around $1.09 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does HUMA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for HUMA. Download the app for real-time alerts.
- How can I analyze Humacyte, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.